AstraZeneca Results Presentation Deck

Financial priorities H1 2021 results underpinned the strategic journey Deleveraging/dividend growth As cash flow improves, deleveraging and progressive dividend policy 24 ● Unchanged priorities for capital allocation. Cash-flow growth 14% growth in reported EBITDA and continued improvement in working capital management ● 2021: anticipate further improvement in cash flow, cash- flow metrics and dividend cover Changes at CER. ● ● Revenue growth +9% growth in total revenue in H1 2021 excl. the pan- demic COVID-19 vaccine Operating leverage 55% ratio of core operating expenses to total revenue (down 3.0 pp) 20% growth in core operating profit ● • 28% core operating profit margin incl. contribution from OOI B

View entire presentation